286 related articles for article (PubMed ID: 21696174)
1. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.
Coteron JM; Marco M; Esquivias J; Deng X; White KL; White J; Koltun M; El Mazouni F; Kokkonda S; Katneni K; Bhamidipati R; Shackleford DM; Angulo-Barturen I; Ferrer SB; Jiménez-Díaz MB; Gamo FJ; Goldsmith EJ; Charman WN; Bathurst I; Floyd D; Matthews D; Burrows JN; Rathod PK; Charman SA; Phillips MA
J Med Chem; 2011 Aug; 54(15):5540-61. PubMed ID: 21696174
[TBL] [Abstract][Full Text] [Related]
2. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Gujjar R; El Mazouni F; White KL; White J; Creason S; Shackleford DM; Deng X; Charman WN; Bathurst I; Burrows J; Floyd DM; Matthews D; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2011 Jun; 54(11):3935-49. PubMed ID: 21517059
[TBL] [Abstract][Full Text] [Related]
3. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.
Gujjar R; Marwaha A; El Mazouni F; White J; White KL; Creason S; Shackleford DM; Baldwin J; Charman WN; Buckner FS; Charman S; Rathod PK; Phillips MA
J Med Chem; 2009 Apr; 52(7):1864-72. PubMed ID: 19296651
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
[TBL] [Abstract][Full Text] [Related]
5. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
[TBL] [Abstract][Full Text] [Related]
6. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Phillips MA; Lotharius J; Marsh K; White J; Dayan A; White KL; Njoroge JW; El Mazouni F; Lao Y; Kokkonda S; Tomchick DR; Deng X; Laird T; Bhatia SN; March S; Ng CL; Fidock DA; Wittlin S; Lafuente-Monasterio M; Benito FJ; Alonso LM; Martinez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Haselden JN; Louttit J; Cui Y; Sridhar A; Zeeman AM; Kocken C; Sauerwein R; Dechering K; Avery VM; Duffy S; Delves M; Sinden R; Ruecker A; Wickham KS; Rochford R; Gahagen J; Iyer L; Riccio E; Mirsalis J; Bathhurst I; Rueckle T; Ding X; Campo B; Leroy D; Rogers MJ; Rathod PK; Burrows JN; Charman SA
Sci Transl Med; 2015 Jul; 7(296):296ra111. PubMed ID: 26180101
[TBL] [Abstract][Full Text] [Related]
7. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
[TBL] [Abstract][Full Text] [Related]
8. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
[TBL] [Abstract][Full Text] [Related]
9. Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase.
Marwaha A; White J; El Mazouni F; Creason SA; Kokkonda S; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2012 Sep; 55(17):7425-36. PubMed ID: 22877245
[TBL] [Abstract][Full Text] [Related]
10. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
White J; Dhingra SK; Deng X; El Mazouni F; Lee MCS; Afanador GA; Lawong A; Tomchick DR; Ng CL; Bath J; Rathod PK; Fidock DA; Phillips MA
ACS Infect Dis; 2019 Jan; 5(1):90-101. PubMed ID: 30375858
[TBL] [Abstract][Full Text] [Related]
11. Identification of 3,4-Dihydro-2
Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
[No Abstract] [Full Text] [Related]
12. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
Deng X; Kokkonda S; El Mazouni F; White J; Burrows JN; Kaminsky W; Charman SA; Matthews D; Rathod PK; Phillips MA
J Med Chem; 2014 Jun; 57(12):5381-94. PubMed ID: 24801997
[TBL] [Abstract][Full Text] [Related]
13. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.
Pippione AC; Sainas S; Goyal P; Fritzson I; Cassiano GC; Giraudo A; Giorgis M; Tavella TA; Bagnati R; Rolando B; Caing-Carlsson R; Costa FTM; Andrade CH; Al-Karadaghi S; Boschi D; Friemann R; Lolli ML
Eur J Med Chem; 2019 Feb; 163():266-280. PubMed ID: 30529545
[TBL] [Abstract][Full Text] [Related]
15. Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.
Palmer MJ; Deng X; Watts S; Krilov G; Gerasyuto A; Kokkonda S; El Mazouni F; White J; White KL; Striepen J; Bath J; Schindler KA; Yeo T; Shackleford DM; Mok S; Deni I; Lawong A; Huang A; Chen G; Wang W; Jayaseelan J; Katneni K; Patil R; Saunders J; Shahi SP; Chittimalla R; Angulo-Barturen I; Jiménez-Díaz MB; Wittlin S; Tumwebaze PK; Rosenthal PJ; Cooper RA; Aguiar ACC; Guido RVC; Pereira DB; Mittal N; Winzeler EA; Tomchick DR; Laleu B; Burrows JN; Rathod PK; Fidock DA; Charman SA; Phillips MA
J Med Chem; 2021 May; 64(9):6085-6136. PubMed ID: 33876936
[TBL] [Abstract][Full Text] [Related]
16. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
[TBL] [Abstract][Full Text] [Related]
18. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
Mandt REK; Lafuente-Monasterio MJ; Sakata-Kato T; Luth MR; Segura D; Pablos-Tanarro A; Viera S; Magan N; Ottilie S; Winzeler EA; Lukens AK; Gamo FJ; Wirth DF
Sci Transl Med; 2019 Dec; 11(521):. PubMed ID: 31801884
[TBL] [Abstract][Full Text] [Related]
19. Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials.
Ojha PK; Roy K
Eur J Med Chem; 2010 Oct; 45(10):4645-56. PubMed ID: 20708304
[TBL] [Abstract][Full Text] [Related]
20. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]